Lyka Labs Share Price

Lyka Labs Limited is a research-driven pharmaceutical company engaged in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs) across various therapeutic segments in India. The company manufactures a diverse range of products including dry powder injections, liquid injections, lyophilized injections, creams, ointments, foams, gels, lotions, and external preparations, covering therapeutic areas such as anti-infectives, dermatology, gastroenterology, intensive care, cosmetology, and pain management. The share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Lyka Labs stock price often mirrors shifts in domestic pharmaceutical demand, API pricing trends, and investor views on the healthcare sector’s growth prospects. Factors such as the pace of new product development, regulatory approvals, raw material cost pressures, and government policies on drug pricing influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Lyka Labs stock price movements.

Lyka Labs live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Lyka Labs live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Lyka Labs share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Lyka Labs Limited Company Fundamentals

a. Company Background

Lyka Labs Limited was incorporated in 1976. The company’s registered office is located in Mumbai, Maharashtra, India. The company was founded on December 29, 1976, and is headquartered in Mumbai, India. Lyka Labs Limited is a pharmaceutical company engaged in the development, manufacture, and marketing of quality finished dosages. The company’s primary activity involves the manufacturing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments. It initially focused on injectable formulations before gradually expanding into a diversified portfolio including creams, ointments, gels, lotions, and external preparations. Over the years, Lyka Labs has significantly expanded its product portfolio and manufacturing capabilities. The company operates in a regulated environment, with its activities governed by the Central Drugs Standard Control Organization (CDSCO). The company has a workforce of approximately 423 to 499 employees. It has a presence in both domestic and international markets, with the majority of its revenue coming from India. The company has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal agents, and other emollients, as well as liquid and lyophilized injectables in the anti-bacterial and antifungal segments. It also offers contracted manufacturing services to various large pharmaceutical companies and provides technical assistance in manufacturing know-how and clinical study data.

b. Product Lines

• Dry powder injections, liquid injections, and lyophilized (freeze-dried) injectable formulations

• Creams, ointments, foams, gels, and lotions for topical and dermatological applications

• Anti-infective products including antibiotics, anti-bacterial, and anti-fungal agents

• Cephalosporin formulations for bacterial infection treatment

• Proton pump inhibitors for gastrointestinal disorders

• Corticosteroid hormones for inflammatory conditions

• Pain management products including topical and systemic painkillers

• Dermatological formulations including emollients, topical steroids, anti-acne products, acne management solutions, skin lightening products, and anti-aging creams

• Cosmeceutical products including hair care products, anti-dandruff shampoo, sunscreen, face washes, and facial scrubs

• Nutraceuticals and anti-oxidant tablets and combinations

• Anti-malarial medications for malaria treatment and prevention

• Bone resorption inhibitors for osteoporosis management

• Intensive care and surgery care products

• Anesthesia-related products for medical procedures

• Urology and wound care products

• Contracted manufacturing services for large pharmaceutical companies

• Technical data services including molecule stability testing, impurity profiling, and BA/BE clinical study data

c. Company Revenue Model

• Primary revenue from the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs) to domestic and international customers

• Volume-driven revenue based on the quantity of formulations sold to hospitals, pharmacies, and distributors

• Revenue from the India segment contributed a total revenue of ₹847.9 million, accounting for approximately 63% of total revenue in FY2025

• Revenue from exports to international markets through distribution networks

• Revenue from contracted manufacturing services to large pharmaceutical companies

• Income from technical assistance in manufacturing know-how, manufacturing facilities setup, and clinical study data provision

• Processing fees and service charges from contract manufacturing arrangements

• Revenue from the sale of products in various forms including injections, creams, ointments, foams, gels, and lotions

• Government policy changes on drug pricing and healthcare spending influencing revenue stability

d. Geographic Presence

• Strong presence across India with registered office and corporate headquarters located in Mumbai, Maharashtra

• Manufacturing facilities located in India with the capability to produce a wide range of pharmaceutical formulations

• Presence in domestic markets across all states of India, with the majority of revenue generated from the India segment (approximately 63% of total revenue)

• Export presence in international markets through distribution networks

• Digital platform enabling customer acquisition across domestic and international markets

• Operations primarily concentrated in India with a growing international footprint through exports

e. Key Milestones

• 1976: Incorporated as Lyka Labs Limited on December 29

• 1976: Headquartered in Mumbai, India

• Expanded manufacturing capabilities to include dry powder, liquid, and lyophilized injections

• Diversified product portfolio to include creams, ointments, foams, gels, lotions, and external preparations

• Developed varied drug delivery systems for topical steroids, painkillers, anti-fungal agents, and other emollients

• Established presence in domestic and international markets

• Listed on National Stock Exchange (NSE) and Bombay Stock Exchange (BSE)

f. Industry Perspective

Lyka Labs Limited operates in the pharmaceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.5 trillion in 2025 and is projected to grow at a CAGR of 3-6% through 2026. In India, the pharmaceutical market is a key driver of economic growth. According to Mordor Intelligence, the India pharmaceutical market is estimated at USD 66.66 billion in 2025 and is expected to reach USD 88.86 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.92% during the forecast period (2025-2030). According to the Economic Survey 2025-26, the sector’s annual turnover reached ₹4.72 lakh crore in FY25. India’s domestic pharmaceutical market, valued at approximately USD 60 billion, is expected to double to about USD 130 billion by 2030. Pharmaceutical exports stood at USD 30.47 billion in 2024-25. The domestic pharmaceutical market posted an 8.1% year-on-year increase in August 2025, with revenue expected to grow between 8-9% in FY26, placing India among the fastest-expanding pharmaceutical markets worldwide. The government aims to increase healthcare spending and access, with the AB-PMJAY scheme receiving increased allocation. Key challenges include regulatory compliance, pricing pressures from the National Pharmaceutical Pricing Authority (NPPA), intense competition from domestic and multinational players, and the upcoming Drugs, Medical Devices and Cosmetics Bill, 2023.

Lyka Labs Limited Stock Market Presence: Listings & Index Representation

Lyka Labs is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol LYKALABS and on the Bombay Stock Exchange (BSE) with the scrip code 500259. The company’s ISIN number is INE933A01014. Its listing on both exchanges ensures that the Lyka Labs share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Lyka Labs is included in indices such as BSE 500, BSE AllCap, and BSE SmallCap on the BSE. Being represented in multiple indices enhances the visibility and liquidity of the Lyka Labs stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Lyka Labs in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Lyka Labs Limited Stock Performance and Share Price History

The Lyka Labs price has exhibited significant volatility over the past decade, shaped by the company’s position in the pharmaceutical sector and broader industry cycles. The Lyka Labs share price recorded a negative total return of approximately 46.0% to 51.7% over the last 1 year (as of April 2026), significantly underperforming the BSE Healthcare index which returned 1.3% to 6.8% during the same period. The Lyka Labs share price delivered a 5-year total return of 15.2% to 98.07% depending on the source, demonstrating mixed long-term performance. The Lyka Labs share price reached a 52-week high of ₹128.78 and a 52-week low of ₹44.10, indicating a wide trading range and substantial price fluctuations of approximately ₹84 from peak to trough. The Lyka Labs share price recorded a strong rally in 2021, delivering a substantial positive annual return of 582.9%, while the subsequent period has seen the Lyka Labs stock price correct significantly from its peak levels. The Lyka Labs share price has shown a 1-month return of approximately -10.9% to -23.13% and a 3-month return of -27.5% to -29.77% as of April 2026, indicating recent consolidation.

The Lyka Labs stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a turnaround from a net loss of ₹26.0 million in FY2024 to a net profit of ₹79.0 million in FY2025, the Lyka Labs stock price showed a positive reaction. The Lyka Labs share price has shown a pattern of positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over raw material costs have contributed to consolidation in the Lyka Labs stock price. Corporate developments, including strategic announcements such as the receipt of an Indian patent for pregabalin gel 8% valid through 2043, have also influenced short-term fluctuations in the Lyka Labs share price. The Lyka Labs share price has shown a 10-year aggregate net profit of negative ₹74.69 crore, reflecting the volatility in the stock. The Lyka Labs share price reached its 52-week high of ₹128.78 before declining to its 52-week low of ₹44.10, reflecting the volatility inherent in the pharmaceutical space. The Lyka Labs share price has shown a year-to-date return of approximately -20.3% to -26.8% as of April 2026, indicating continued pressure in the current fiscal year. Comprehending these patterns in the Lyka Labs share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Lyka Labs stock price movements illustrate how industry fundamentals, regulatory cycles, and investor expectations converge in market pricing.

The Lyka Labs share price has shown distinct seasonal patterns over the past decade. In terms of annual performance, the Lyka Labs share price delivered its strongest annual return of 582.9% in 2021, followed by a positive return of 57.4% in 2020, and 27.9% in 2024. The stock recorded negative annual returns in 2025 (-51.7%), 2022 (-41.7%), 2019 (-35.1%), 2023 (-4.6%), and 2026 year-to-date. The Lyka Labs share price has demonstrated that the stock tends to perform better in periods of strong pharmaceutical demand and favourable export conditions, while underperforming during phases of regulatory uncertainty and intense competition.

Lyka Labs Limited Investor Relevance and Role in Portfolio

Lyka Labs holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on formulations and active pharmaceutical ingredients. The company’s diversified product portfolio across injectables, topical formulations, and cosmeceuticals, along with its contracted manufacturing services, aligns it with investment strategies that value manufacturing scale and product diversification. The Lyka Labs price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor API pricing trends, regulatory approvals, and healthcare spending indicators when evaluating allocation decisions.

Institutional stakeholders play a significant role in Lyka Labs’ ownership profile, with notable long term investment entities such as Ipca Laboratories Limited being the largest shareholder at approximately 40.98%, and Thermo Capital Private Limited (1.55%) among key shareholders identified in institutional holdings data. Mutual fund holders of Lyka Labs hold 0.01% stake in the company. As of December 2025, promoters hold 58.16% of the company, Foreign Institutional Investors (FIIs) hold 0.17%, Domestic Institutional Investors (DIIs) hold 0.66%, Mutual Funds hold 0.01%, and Retail holds approximately 41.00% of Lyka Labs. Promoters’ stake has remained stable at 58.16% over recent quarters. FII holdings have decreased from 0.23% in March 2025 to 0.17% in December 2025, while DII holdings have remained stable at 0.66% over the same period. Mutual Fund holdings have remained unchanged at 0.01%. These investors represent a blend of domestic and institutional perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta analysis of Lyka Labs across multiple time periods highlights its changing volatility in relation to the overall market. Based on data, the 5-year beta stands at approximately 0.16 to 0.71, indicating that the stock is generally less volatile than the broader market over an extended period. In short-term analysis, beta values from other sources show 0.71 (LTM), 0.16 (5-year), and negative beta in some calculations. Based on data from Simply Wall St, the beta is 0.16 as of February 2026. Based on data from IndStocks, the beta (LTM) is 0.71. Based on data from Investing.com JP, the P/E ratio TTM is 788.88. The stock’s weekly volatility of approximately 6-7% has been stable over the past year. The average weekly movement of Lyka Labs stock is approximately 5-7%, compared to the pharmaceutical industry average of 4-5% and the market average of 5-6%, indicating higher volatility than its industry and similar to the broader market. The Lyka Labs share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Lyka Labs stock price’s low beta reflects that the company’s established market position and diversified product portfolio may provide some stability, though the pharmaceutical sector remains sensitive to regulatory changes and drug price fluctuations.

Lyka Labs Limited Sectoral Relevance and Peer Positioning

The sector relevance of Lyka Labs is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other diversified drug manufacturing companies. As part of this industry, the company’s strategic positioning connects formulations across multiple therapeutic categories serving healthcare needs across domestic and international markets. Competitors in the pharmaceutical segment include companies such as Venus Remedies Limited, Godavari Drugs Limited, Bal Pharma Limited, Ipca Laboratories Limited, and other specialized players. Ipca Laboratories is also the largest shareholder in Lyka Labs, holding approximately 40.98% stake. Firms with parallels in either product portfolio scale or manufacturing capabilities are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Lyka Labs P/E ratio have shown significant variations over different periods. The mean historical P/E ratio has varied widely, with the current P/E ratio not available or negative as TTM earnings are negative. The P/B ratio of Lyka Labs stands at approximately 1.9 to 2.67 times, representing a slight premium to its peers’ median range of 1.86 times. The Lyka Labs P/E ratio has shown extreme fluctuations, with ratios ranging from 33.51 to 788.88 in various periods, reflecting volatile earnings and changing investor perceptions of the company’s earnings potential.

Similarly, the Lyka Labs EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from new product launches and capacity utilization supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material inflation and regulatory changes have moderated EPS momentum. Lyka Labs earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Lyka Labs market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market, currently standing at approximately ₹196 crore to ₹215 crore.

Over the last ten years, the market capitalisation of Lyka Labs has followed a pattern of significant volatility with periods of growth followed by sharp declines. From fiscal year 2020 onwards, the company’s market cap showed an increasing trend, reflecting strong investor confidence during the pharmaceutical sector recovery. The market cap increased from lower levels to reach a peak of approximately ₹215 crore in 2025-26. However, the market cap has shown significant fluctuations, with values ranging from ₹186.62 crore to ₹215 crore in recent periods. The 5-year CAGR of market cap is approximately 19.61%, reflecting overall growth despite recent volatility. This growth reflects investor confidence in the company’s product portfolio and manufacturing capabilities, though the pharmaceutical sector’s overall performance relative to broader market indices has been mixed.

The earnings history of Lyka Labs over the past five years (FY2021 to FY2025) has been characterised by a period of volatility followed by recent recovery. Net income showed a highly volatile trend, with reported net profit of ₹39.00 crore in FY2022, a net loss of ₹13.21 crore in FY2023, a net loss of ₹2.49 crore in FY2024, and recovering to a net profit of ₹7.93 crore in FY2025. Total revenue increased from ₹93.07 crore in FY2023 to ₹111.19 crore in FY2024 (19.5% growth) and further to ₹138.50 crore in FY2025 (24.6% growth). The 10-year aggregate net profit stands at negative ₹74.69 crore. Quarterly performance in Q3 FY2025-26 showed net sales of ₹30.73 crore, reflecting near-term earnings volatility. This recent earnings recovery reflects the impact of operational efficiency, cost optimization, and revenue growth on the company’s profitability.

The Earnings Per Share (EPS) history for Lyka Labs has shown significant variation over the past decade. The diluted EPS growth rate has shown variation, with EPS at ₹13.57 in FY2022, negative ₹4.63 in FY2023, negative ₹0.79 in FY2024, and positive ₹2.22 in FY2025. The current TTM EPS stands at approximately negative ₹0.1 to negative ₹0.2 depending on the source. Over a five-year period, the company demonstrated volatile EPS performance, with the highest EPS recorded in FY2022 at ₹13.57, while the lowest was in FY2023 at negative ₹4.63. Recent quarters have shown EPS of approximately negative ₹0.1, reflecting ongoing earnings volatility.

The Price-to-Earnings (P/E) ratio history of Lyka Labs has shown extreme fluctuations over the five-year period due to volatile earnings. At the end of recent fiscal years, the P/E ratio varied, with 2021 at 33.51, 2022 at 131.04, 2023 at 44.83, and recent data showing negative ratios or not available. The mean historical P/E ratio over the last five years has been around 40-50 times when earnings were positive. The current P/E ratio is not available as TTM earnings are negative, reflecting that investor expectations are adjusting to near-term earnings headwinds. The Lyka Labs share price has been influenced by these valuation metrics. The Lyka Labs price continues to be evaluated in the context of its earnings potential and market position.

Summary

Lyka Labs is a leading pharmaceutical formulations and API company in India listed on both the NSE and BSE, where the Lyka Labs share price reflects domestic healthcare spending cycles, drug pricing regulations, and export demand within the pharmaceutical sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare access themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharmaceutical market.